These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 4027124)

  • 1. Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients--relationship to the debrisoquine hydroxylation metabolic ratio.
    Nordin C; Siwers B; Benitez J; Bertilsson L
    Br J Clin Pharmacol; 1985 Jun; 19(6):832-5. PubMed ID: 4027124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nortriptyline and debrisoquine hydroxylations in Ghanaian and Swedish subjects.
    Woolhouse NM; Adjepon-Yamoah KK; Mellström B; Hedman A; Bertilsson L; Sjöqvist F
    Clin Pharmacol Ther; 1984 Sep; 36(3):374-8. PubMed ID: 6467797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin.
    Baumann P; Jonzier-Perey M; Koeb L; Küpfer A; Tinguely D; Schöpf J
    Int Clin Psychopharmacol; 1986 Apr; 1(2):102-12. PubMed ID: 3571939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation.
    Mellström B; Bertilsson L; Säwe J; Schulz HU; Sjöqvist F
    Clin Pharmacol Ther; 1981 Aug; 30(2):189-93. PubMed ID: 7249504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications.
    Bertilsson L; Mellström B; Sjökvist F; Mårtenson B; Asberg M
    Lancet; 1981 Mar; 1(8219):560-1. PubMed ID: 6111662
    [No Abstract]   [Full Text] [Related]  

  • 6. Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants.
    Bertilsson L; Aberg-Wistedt A; Gustafsson LL; Nordin C
    Ther Drug Monit; 1985; 7(4):478-80. PubMed ID: 4082245
    [No Abstract]   [Full Text] [Related]  

  • 7. Oxidation of tricyclic antidepressant drugs, debrisoquine and 7-ethoxyresorufin, by human liver preparations.
    von Bahr C; Birgersson C; Morgan ET; Eriksson O; Göransson M; Spina E; Woodhouse K
    Xenobiotica; 1986 May; 16(5):391-400. PubMed ID: 3739365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between nortriptyline and debrisoquine hydroxylation in the human liver.
    von Bahr C; Birgersson C; Blanck A; Göransson M; Mellström B; Nilsell K
    Life Sci; 1983 Aug; 33(7):631-6. PubMed ID: 6410141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amitriptyline metabolism: relationship to polymorphic debrisoquine hydroxylation.
    Mellström B; Bertilsson L; Lou YC; Säwe J; Sjöqvist F
    Clin Pharmacol Ther; 1983 Oct; 34(4):516-20. PubMed ID: 6617075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Relationship between amitriptyline metabolism and polymorphic debrisoquine hydroxylation in native Chinese volunteers].
    Zhang XH; Yu P; Gu NF; Yin JL; Jiang WD
    Yao Xue Xue Bao; 1993; 28(2):85-91. PubMed ID: 8328289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of nortriptyline and paroxetine on CYP2D6 activity in depressed elderly patients.
    Solai LK; Pollock BG; Mulsant BH; Frye RF; Miller MD; Sweet RA; Kirshner M; Sorisio D; Begley A; Reynolds CF
    J Clin Psychopharmacol; 2002 Oct; 22(5):481-6. PubMed ID: 12352271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism.
    Alván G; Grind M; Graffner C; Sjöqvist F
    Clin Pharmacol Ther; 1984 Oct; 36(4):515-9. PubMed ID: 6478737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man.
    Bertilsson L; Eichelbaum M; Mellström B; Säwe J; Schulz HU; Sjöqvist F
    Life Sci; 1980 Nov; 27(18):1673-7. PubMed ID: 7442467
    [No Abstract]   [Full Text] [Related]  

  • 14. Interethnic dissociation between debrisoquine and desipramine hydroxylation.
    Rudorfer MV; Lane EA; Potter WZ
    J Clin Psychopharmacol; 1985 Apr; 5(2):89-92. PubMed ID: 3988975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
    Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
    Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of southern Africa.
    Sommers DK; Moncrieff J; Avenant J
    Hum Toxicol; 1988 May; 7(3):273-6. PubMed ID: 3391625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A population and familial study of the defective alicyclic hydroxylation of debrisoquine among Egyptians.
    Mahgoub A; Idle JR; Smith RL
    Xenobiotica; 1979 Jan; 9(1):51-6. PubMed ID: 760321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Debrisoquine oxidative phenotyping and psychiatric drug treatment.
    Derenne F; Joanne C; Vandel S; Bertschy G; Volmat R; Bechtel P
    Eur J Clin Pharmacol; 1989; 36(1):53-8. PubMed ID: 2563689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.
    Bertilsson L; Dengler HJ; Eichelbaum M; Schulz HU
    Eur J Clin Pharmacol; 1980 Feb; 17(2):153-5. PubMed ID: 7371707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment.
    Brøsen K; Gram LF; Haghfelt T; Bertilsson L
    Pharmacol Toxicol; 1987 Apr; 60(4):312-4. PubMed ID: 3588528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.